Low-dose infigratinib, an oral selective fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, demonstrates activity in preclinical models of FGFR3-related disorders-MedSci.cn

Low-dose infigratinib, an oral selective fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, demonstrates activity in preclinical models of FGFR3-related disorders

Muslimova, E; Demuynck, B; Loisay, L; Dambkowski, C; Legeai-Mallet, L

HORMONE RESEARCH IN PAEDIATRICS, 2023; 96 (SUPPL 2): 29

科室
- - 订阅+
  - 更多科室
工具
服务